CAPS
Study of the Relation Between the Consumption of Psychoactive Substances and Pain, in Patients Suffering or Surviving From Cancer and Followed in France: Cross-sectional Pilot Study
Sponsor study identifier
observational
2,010
1 country
1
Study Start
January 27, 2023
Actual (reported)Primary Completion
March 20, 2023
Actual (reported)Study Completion
March 20, 2023
Actual (reported)Pain is one of the most prevalent symptoms during and after cancer. Pain can be the consequence of several situations (disease progression, surgery, and anticancer drugs). However, pain can frequently be associated with a substance use disorder (alcohol, tobacco, drugs, and illicit products such as cannabis). The relationship between substance use and pain is known to be complex and interdependent, i.e. pain can reinforce substance use and substance use can promote pain. However, few data in the literature are available on the use of psychoactive substances in relation to pain in the context of cancer (cancer patients and cancer survivors). Moreover, the scientific literature agrees on the fact that these elements are little studied and underestimated in the clinic. The investigators hypothesize that, in cancer patients or cancer survivors, the prevalence of the use of psychoactive substances would be higher in the presence of pain, and would be associated with its intensity and its impact on the quality Health-Related Living (HRQoL). The main objective of this study will be to compare, in an adult population of patients suffering from cancer or having had cancer, the prevalence of the consumption of psychoactive substances in painful patients compared to non-painful patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 20, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 4, 2023
Actual (reported)January 13, 2023
Actual (reported)January 27, 2023
Actual (reported)March 20, 2023
Actual (reported)March 20, 2023
Actual (reported)substance use
Legal: alcohol, tobacco, electronic cigarette, psychotropic drugs (benzodiazepines, z-drugs, and opioids), CBD, and other susbtances Illegal: cannabis, and other drugs At least once in the past year, at least once in the past month, at least once in the past week, or at least once a day
day 1
Pain severity
day 1
Neuropathic pain
day 1
Analgesic use
day 1
Chemotherapy-induced peripheral neuropathy
day 1
Health-related quality of life and symptoms
day 1
answer to an online questionnaire
Online self-administered questionnaire exploring substance use, pain, chemotherapy-induced peripheral neuropathy, health-related quality of life, anxiety, depression, social and material deprivation, patients and oncological charactericitcs, and intercurrent pathologies
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Cancer patients and cancer survivors recruited thanks to associations of cancer patients and social networks
CHU Clermont-Ferrand
Clermont-Ferrand, France
Ragusa C, Pereira B, Balayssac D. Assessment of pain prevalence in cancer patients undergoing anticancer treatments and in cancer survivors after completion of anticancer treatments: A French nationwide cross-sectional study. Int J Cancer. 2025 May 15;156(10):1873-1884. doi: 10.1002/ijc.35280. Epub 2024 Dec 3.
Ragusa C, Pereira B, Balayssac D. Study of the relationship between psychoactive substance use and pain in cancer patients and cancer survivors: A French nationwide cross-sectional study. Int J Cancer. 2024 Sep 15;155(6):1078-1090. doi: 10.1002/ijc.35006. Epub 2024 May 15.
2,010 participants (actual enrollment reported by the registry).
First Submitted
January 4, 2023
First Posted
January 13, 2023
Study Start
January 27, 2023
Actual (reported)Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics
Contact the study team to confirm eligibility.
Primary Completion
March 20, 2023
Actual (reported)Study Completion
March 20, 2023
Actual (reported)Last Updated
June 13, 2023
Record last verified: 2022-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: